1. Home
  2. PRTA vs MEVO Comparison

PRTA vs MEVO Comparison

Compare PRTA & MEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.15

Market Cap

429.2M

Sector

Health Care

ML Signal

N/A

MEVO

M Evo Global Acquisition Corp II Class A Ordinary Shares

SELL

Current Price

$10.05

Market Cap

397.2M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
PRTA
MEVO
Founded
2012
2025
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
429.2M
397.2M
IPO Year
2013
2025

Fundamental Metrics

Financial Performance
Metric
PRTA
MEVO
Price
$8.15
$10.05
Analyst Decision
Buy
Analyst Count
7
0
Target Price
★ $21.40
N/A
AVG Volume (30 Days)
★ 420.1K
83.9K
Earning Date
11-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $814,000.00
N/A
Revenue This Year
$775.41
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.70
$9.83
52 Week High
$11.80
$11.14

Technical Indicators

Market Signals
Indicator
PRTA
MEVO
Relative Strength Index (RSI) 45.82 61.24
Support Level $8.01 $10.00
Resistance Level $9.14 $10.07
Average True Range (ATR) 0.44 0.01
MACD -0.01 0.00
Stochastic Oscillator 37.55 71.43

Price Performance

Historical Comparison
PRTA
MEVO

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About MEVO M Evo Global Acquisition Corp II Class A Ordinary Shares

M Evo Global Acquisition Corp II is a blank check special purposr acquisition company.

Share on Social Networks: